Indian Pharma Market Expands 4.5% In January; Growth Trajectory Maintained: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
The Indian pharma sector has retained its growth momentum for the fifth consecutive month.
After growing 8.5% in December, it grew 4.5% in January, signalling that the post-Covid-19 recovery is in full swing.
Overall, acute therapies grew 1.4%; chronic and sub-chronic therapies, 6.1% and 8.6% respectively.
Dec volumes were down 2.9%, while the sector hiked prices 4.9% and growth from launches was back to 2.4% as the number of Covid-19 cases is now coming down.
Growth in key Covid-19 molecules like remdesivir (monthly sales: Rs 388 million) and favipiravir (Rs 159 million) is slowing. We expect healthy single-digit volume growth.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.